Is Clinuvel Pharmaceuticals Limited (CLVLY) a Buy, Sell, or Hold?
OTC : CLVLY
Clinuvel Pharmaceuticals Limited — News
$6.95 USD
$0 (0.0%)
- Volume
- 21.66K
- Average Volume
- 3K
- Market Capitalization
- $350.47M
- P/E Ratio
- 15.48
- Dividend Yield
- 0.50%
- Price Target
- Year High
- $9.00
- Year Low
- $5.98
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.08
- Current Ratio
- $14.64
| Source | Headline |
|---|---|
|
CLINUVEL implements strategic reorganisation to refocus on U.S. markets
MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce, effective 1 January 2027, concurrent with the relocation of its corporate headquarters to the United States. globenewswire.com - 2026-07-23 00:10:00 |
|
CLINUVEL's ADS to commence trading on Nasdaq
MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is expected to commence trading on the Nasdaq Stock Market (Nasdaq) later today (New York time) under the ticker symbol CUVL. The announcement follows the declaration from the U.S. Securities and Exchange Commission (SEC) on 17 July that the Company's publicly filed 20-F Registration Statement is deemed effective, and approval received from Nasdaq to list the ADS. globenewswire.com - 2026-07-20 01:37:00 |
|
SCENESSE® approved for EPP in Canada
Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder globenewswire.com - 2026-07-13 01:10:00 |
